[
  {
    "ts": null,
    "headline": "A Look at Amgen’s (AMGN) Valuation as Repatha Scores Major Trial Win and Direct Sales Launch Spurs Optimism",
    "summary": "Amgen (AMGN) is making waves after its VESALIUS-CV Phase 3 trial demonstrated that Repatha significantly lowers major cardiovascular events in at-risk patients who have not had a prior heart attack or stroke. Adding to this momentum, Amgen introduced AmgenNow, a new direct-to-patient program. The initiative makes Repatha available at a much lower cash price, aiming to broaden access and potentially increase future uptake among patients. See our latest analysis for Amgen. Amgen's momentum has...",
    "url": "https://finnhub.io/api/news?id=6bc15764046714a046a9c04f2d4b66917129578a071b91ea938cdaba787d01ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760635119,
      "headline": "A Look at Amgen’s (AMGN) Valuation as Repatha Scores Major Trial Win and Direct Sales Launch Spurs Optimism",
      "id": 137121956,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) is making waves after its VESALIUS-CV Phase 3 trial demonstrated that Repatha significantly lowers major cardiovascular events in at-risk patients who have not had a prior heart attack or stroke. Adding to this momentum, Amgen introduced AmgenNow, a new direct-to-patient program. The initiative makes Repatha available at a much lower cash price, aiming to broaden access and potentially increase future uptake among patients. See our latest analysis for Amgen. Amgen's momentum has...",
      "url": "https://finnhub.io/api/news?id=6bc15764046714a046a9c04f2d4b66917129578a071b91ea938cdaba787d01ca"
    }
  },
  {
    "ts": null,
    "headline": "Amgen (NASDAQ:AMGN) Seems To Use Debt Quite Sensibly",
    "summary": "Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...",
    "url": "https://finnhub.io/api/news?id=d981a7b044d5c75f8ebaf2aced1d40ab046c059ff64799f31dc76b0dd39153a2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760616012,
      "headline": "Amgen (NASDAQ:AMGN) Seems To Use Debt Quite Sensibly",
      "id": 137104590,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...",
      "url": "https://finnhub.io/api/news?id=d981a7b044d5c75f8ebaf2aced1d40ab046c059ff64799f31dc76b0dd39153a2"
    }
  },
  {
    "ts": null,
    "headline": "Oppenheimer Highlights Amgen’s (AMGN) Strong Revenue Growth and Breakthrough in Cardiovascular Study",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is included among the 11 Defensive Healthcare Dividend Stocks to Buy Now. Amgen Inc. (NASDAQ:AMGN) is a California-based biopharmaceutical company. On October 3, Op⁠penheimer reaffirm‍ed its‌ O‌utpe‍rform ratin‌g on Amgen Inc. (NASDAQ:AMGN) with a price target of $​380. The‌ firm high‌lighted Amgen’s solid performance and al‌so repor⁠ted tha‌t‌ its VESALIUS-CV trial reached […]",
    "url": "https://finnhub.io/api/news?id=3617fb63edf477a1779fc63cbe2622c46a67d05ed718f0026ec91a4c0c25dcf5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760594354,
      "headline": "Oppenheimer Highlights Amgen’s (AMGN) Strong Revenue Growth and Breakthrough in Cardiovascular Study",
      "id": 137102074,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) is included among the 11 Defensive Healthcare Dividend Stocks to Buy Now. Amgen Inc. (NASDAQ:AMGN) is a California-based biopharmaceutical company. On October 3, Op⁠penheimer reaffirm‍ed its‌ O‌utpe‍rform ratin‌g on Amgen Inc. (NASDAQ:AMGN) with a price target of $​380. The‌ firm high‌lighted Amgen’s solid performance and al‌so repor⁠ted tha‌t‌ its VESALIUS-CV trial reached […]",
      "url": "https://finnhub.io/api/news?id=3617fb63edf477a1779fc63cbe2622c46a67d05ed718f0026ec91a4c0c25dcf5"
    }
  }
]